Examining the Effects of Doctors' Night Shifts on Sleep

UMIN ID: UMIN000056718

Registered date:30/01/2025

Basic Information

• Recruitment status: Pending
• Health condition(s) or Problem(s) studied: Sleep disorders
• Date of first enrollment: 2025/02/01
• Target sample size: 25
• Countries of recruitment: Japan
• Study type: Observational

Outcome(s)

• Primary Outcome: The difference in the duration of non-REM sleep stage 3 measured by sleep EEG between nighttime sleep following daytime work and nighttime sleep following a night shift.
• Secondary Outcome: The difference in sleep onset latency measured by sleep EEG between nighttime sleep following daytime work and nighttime sleep following a night shift. The correlation between sleep EEG parameters and subjective sleep restoration the following morning. The correlation between sleep EEG parameters and the LF/HF ratio the following morning. The correlation between sleep EEG parameters and the urinary cortisol-to-creatinine ratio the following morning. The correlation between sleep EEG parameters and the postprandial glucose incremental area under the curve (iAUC) the following morning. The difference in subjective sleep restoration between waking after a day shift and waking after a night shift. The difference in the LF/HF ratio between waking after a day shift and waking after a night shift. The difference in the urinary cortisol-to-creatinine ratio between waking after a day shift and waking after a night shift. The difference in the postprandial glucose incremental area under the curve (iAUC) between waking after a day shift and waking after a night shift. The correlation between the standard deviation of nighttime sleep duration, as measured by actigraphy, and both the average glucose levels and the standard deviation of glucose levels during the observation period.

Key inclusion & exclusion criteria

• Age minimum: Not applicable
• Age maximum: Not applicable
• Gender: Male and Female
• Exclude criteria: Individuals taking hypnotics or sleep-improving medications. Individuals receiving treatment for arrhythmia, myocardial infarction, or heart failure. Individuals diagnosed with hypertension, sleep apnea syndrome, diabetes mellitus, or dyslipidemia. Individuals on continuous oral or intravenous steroid therapy. Individuals receiving treatment for liver, kidney, or pancreatic diseases. Individuals with severe underweight, defined as a BMI less than 16 kilograms per square meter, or severe obesity, defined as a BMI of 35 kilograms per square meter or greater. Smokers. Individuals with a history of international travel within two weeks prior to the start of observation. Individuals with allergies to wheat, eggs, milk components, soy, or oranges. Any individual deemed unsuitable for participation in this study by the principal investigator or sub-investigators.

Related Information

• Primary Sponsor: Kyoto University Hospital
• Source(s) of Monetary Support: Ministry of Education, Culture, Sports, Science and Technology